Splash Beverage Group acquires global rights to CannEpil, secures financing and 20-year license
Seeking Alpha ·
Splash Beverage Group ( SBEV ) has entered into an exclusive global licensing agreement with Argent BioPharma Limited ( RGT ) for CannEpil, a proprietary, patent-protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.
DYAX Investor Sentiment
Bullish (Long) 45% · Bearish (Short) 55%
408 participants
Related News
- Rivian shares slide as EV maker to raise capital through stock offering
- Cognizant expands AI partnership with Google Cloud; targets 200K Gemini users
- SpaceX to join the Nasdaq 100: How Wall Street feels about the Elon Musk story
- Saturn Cloud Launches on Nebius Marketplace for Self-Service Deployment
- Lumen21, L&L Consulting Services, and TechWise Group Merge to Form a Unified Microsoft Partner
- Diversification, not stock picking, is the key to long-term returns, Clem Chambers says